Reply: Letter: Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 COURAGE Trial
Reply: Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial
Authors
- David Staskin (ORCID: https://orcid.org/0000-0003-4972-765X)
- Janet Owens‐Grillo (ORCID: https://orcid.org/0009-0003-2457-2214)
- Eric Rovner (ORCID: https://orcid.org/0000-0003-3950-8752)
- Elizabeth Thomas (ORCID: https://orcid.org/0000-0002-5224-1119)
Institutions
- Tufts University (US)
- Medical University of South Carolina (US)
- Sumitomo Dainippon Pharma (United States) (US)
Publication Details
- Journal
- The Journal of Urology
- Published
- 2024-10-23
- DOI
- https://doi.org/10.1097/ju.0000000000004291
- Primary Topic
- Urinary Bladder and Prostate Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00